Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
OwnerTimothy J. O'Brieninventor
Life of this patent
Estimating the term…
Abstract
The present invention provides a transmembrane serine protease TADG-12 protein, splice variants of the TADG-12 protein and DNA fragments encoding such proteins. Also provided are vectors and host cells capable of expressing the DNAs. The present invention further provides various methods of early detection and therapies of associated ovarian and other malignancies by utilizing the DNAs and/or proteins disclosed herein.
Claims28
A DNA fragment encoding a Tumor Associated Differentially-Expressed Gene-12 (TADG-12) protein or splicing variant of TADG-12, said DNA comprising:
- (a) an isolated DNA fragment encoding a TADG-12 protein that has the amino acid sequence of SEQ ID NO:
- 2;
- (b) an isolated DNA fragment encoding a TADG-12 splicing variant that has an amino acid sequence comprising part of SEQ ID NO. 2;
- and
- (c) an isolated DNA fragment differing from the isolated DNA fragments of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-12 protein or a splicing variant of TADG-12.
An isolated and purified TADG-12 splicing variant protein encoded for by a DNA comprising:
- (a) isolated DNA encoding a TADG-12 splicing variant, said variant protein having an amino acid sequence comprising part of SEQ ID NO. 2;
- and
- (b) isolated DNA differing from the isolated DNA of (a) above in codon sequence due to the degeneracy of the genetic code, and which encodes a splicing variant of TADG-12.
A method for detecting malignant hyperplasia in a biological sample, comprising:
- (a) isolating mRNA from the sample;
- and
- (b) detecting in the sample mRNA encoding a TADG-12 splicing variant protein, wherein the presence of the mRNA in said sample indicates the presence of malignant hyperplasia, wherein the absence of the mRNA in the sample indicates the absence of malignant hyperplasia.
A method for detecting malignant hyperplasia in a biological sample, comprising:
- (a) isolating protein from the sample;
- and
- (b) detecting in said sample a TADG-12 splicing variant protein, wherein the presence of the TADG-12 splicing variant protein in said sample indicates the presence of malignant hyperplasia, wherein the absence of the TADG-12 protein variant in said sample indicates the absence of malignant hyperplasia.
A method of targeted therapy to an individual, comprising:
- administering to an individual a compound having a targeting moiety and a therapeutic moiety, wherein the targeting moiety is specific for a TADG-12 splicing variant protein.
A method of vaccinating an individual against TADG-12, comprising:
- inoculating the individual with a TADG-12 splicing variant protein or fragment thereof, wherein the inoculation elicits an immune response in the individual, thereby vaccinating said individual against TADG-12.
Dependencies are inferred from the claim text.